AbbVie's Next Big Moneymaker? This Drug Just Took a Huge Step Toward Approval
I'm PortAI, I can summarize articles.
AbbVie received a positive opinion from the European Medicines Agency for upadacitinib (RINVOQ) to treat giant cell arteritis (GCA). If approved by the European Commission in 2025, it would be the first oral advanced therapy for GCA. This follows promising results from AbbVie's Phase 3 SELECT-GCA trial. The approval could significantly enhance AbbVie's immunology portfolio and revenue, especially as it faces competition from biosimilars to Humira. Investors are closely monitoring this development as it could be pivotal for AbbVie's growth in the biopharma sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: GuruFocus The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments